Market closedNon-fractional
Replimune/REPL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Ticker
REPL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Woburn, United States
Employees
331
Website
www.replimune.com
Replimune Metrics
BasicAdvanced
$716M
Market cap
-
P/E ratio
-$3.24
EPS
1.26
Beta
-
Dividend rate
Price and volume
Market cap
$716M
Beta
1.26
Financial strength
Current ratio
10.724
Quick ratio
10.525
Long term debt to equity
19.223
Total debt to equity
20.258
Interest coverage (TTM)
-34.96%
Management effectiveness
Return on assets (TTM)
-25.66%
Return on equity (TTM)
-46.42%
Valuation
Price to book
1.73
Price to tangible book (TTM)
1.73
Price to free cash flow (TTM)
-3.65
Growth
Earnings per share change (TTM)
8.27%
3-year earnings per share growth (CAGR)
22.85%
What the Analysts think about Replimune
Analyst Ratings
Majority rating from 9 analysts.
Replimune Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$0
NaN%
Net income
-$55M
7.63%
Profit margin
0.00%
NaN%
Replimune Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
-$0.75
-$0.90
-$0.77
-$0.82
-
Expected
-$0.84
-$0.86
-$0.93
-$0.79
-$0.87
Surprise
-11.14%
5.18%
-16.99%
3.47%
-
Replimune News
AllArticlesVideos
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·2 months ago
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
GlobeNewsWire·2 months ago
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Replimune stock?
Replimune (REPL) has a market cap of $716M as of July 27, 2024.
What is the P/E ratio for Replimune stock?
The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of July 27, 2024.
Does Replimune stock pay dividends?
No, Replimune (REPL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Replimune dividend payment date?
Replimune (REPL) stock does not pay dividends to its shareholders.
What is the beta indicator for Replimune?
Replimune (REPL) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Replimune stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.